There are currently 917 clinical trials in Washington, District Of Columbia looking for participants to engage in research studies. Trials are conducted at various facilities, including Children's National Medical Center, MedStar Georgetown University Hospital, MedStar Washington Hospital Center and Walter Reed Army Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
NCT06097260
Recruiting
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
06/11/2024
Locations: MedStar Georgetown University Hospital, Washington, District of Columbia
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)
NCT05459129
Recruiting
This is a Phase Ib/II, open-label, multicenter, randomized, umbrella study in participants with locally advanced squamous cell carcinoma of the head and neck (SCCHN). The study will enroll treatment-naive participants with resectable Stage III-IVA human papillomavirus (HPV)-negative, programmed death-ligand 1 (PD-L1)-positive SCCHN with measurable disease, as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) who have not received sy... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: The George Washington Cancer Center, Washington, District of Columbia
Conditions: Squamous Cell Carcinoma of the Head and Neck
Register for Updates
Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer
NCT05501548
Recruiting
This is a study to evaluate the safety and clinical activity of the combination of olaparib and high-dose IV ascorbate, as second or later line of therapy, in castration resistant prostate cancer patients with no known DNA repair gene mutations (DDRm). In brief, the primary endpoint is PSA50 response , defined by a 50% reduction in PSA from baseline . The secondary endpoints are assessing the PSA doubling time, radiographic and PSA PFS, safety and tolerability as defined by the incidence of grad... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Sibley Memorial Hospital, Washington, District of Columbia
Conditions: Prostate Cancer, Castration-resistant Prostate Cancer
Register for Updates
Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
NCT03876769
Recruiting
This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in de novo HR pediatric and young adult B-ALL patients who received first-line treatment and are EOC MRD positive. The study will have the following sequential phases: screening, pre-treatment, treatment & follow-up, and survival. After tisagenlecleucel infusion, patient will have assessments performed more frequently in the first month and then at Day 29, then every 3 months f... Read More
Gender:
All
Ages:
Between 1 year and 25 years
Trial Updated:
06/10/2024
Locations: Childrens National Hospital, Washington, District of Columbia
Conditions: B-Cell Acute Lymphoblastic Leukemia
Register for Updates
Zenith® Fenestrated+ Clinical Study
NCT04875429
Recruiting
The Zenith® Fenestrated+ Endovascular Graft Clinical Study will assess the safety and effectiveness of the Zenith® Fenestrated+ Endovascular Graft (ZFEN+) in combination with the BeGraft Balloon-Expandable FEVAR Bridging Stent Graft System (BeGraft) and Unibody2 for the treatment of patients with aortic aneurysms involving one or more of the major visceral arteries.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Medstar Washington Hospital Center, Washington, District of Columbia
Conditions: Aortic Aneurysm, Abdominal, Juxtarenal Aortic Aneurysm, Extent IV Thoracoabdominal, Pararenal Aneurysm
Register for Updates
Implementing Models for Mechanical Circulatory Support Presurgical Assessment in Congenital Heart Disease Treatment
NCT03891160
Recruiting
The purpose of this research study is to look at the advantages of using a 3D printed heart model for surgical planning in children who have been diagnosed with Congenital Heart Disease (CHD) and clinical heart failure and will undergo a ventricular assist device (VAD) placement. The investigators want to study the correlation of having a 3D printed model with improvement in patient outcomes and compare those with patients who have had a VAD placement without a 3D model.
Gender:
All
Ages:
All
Trial Updated:
06/10/2024
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Congenital Heart Disease
Register for Updates
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
NCT05512377
Recruiting
This study is open to adults with advanced cancer in the biliary tract, pancreas, lung, or bladder. This is a study for people for whom previous treatment was not successful or no treatment exists. The purpose of this study is to find out whether a medicine called BI 907828 helps people with cancer in the biliary tract, pancreas, lung, or bladder. BI 907828 is a so-called MDM2 inhibitor that is being developed to treat cancer. All participants take BI 907828 as a tablet once every 3 weeks. Part... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, Washington, District of Columbia
Conditions: Pancreatic Neoplasms, Solid Tumors, Biliary Tract Cancer, Lung Neoplasms, Bladder Cancer
Register for Updates
A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
NCT04886804
Recruiting
The study has 2 parts. The first part is open to adults with different types of advanced cancer (solid tumours with changes in the HER2 gene) for whom previous treatment was not successful. The second part is open to people with non-small cell lung cancer with a specific mutation in the HER2 gene. The purpose of the first study part is to find the highest dose of a medicine called zongertinib the participants can tolerate. Once this dose is found, it will be used in the second study part to te... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Georgetown University, Washington, District of Columbia
Conditions: Neoplasm Metastasis, Non-Small Cell Lung Cancer
Register for Updates
Intratumoral PH-762 for Cutaneous Carcinoma
NCT06014086
Recruiting
The goal of this clinical trial is to evaluate the safety and tolerability of intratumoral injections of PH-762 in squamous cell carcinoma, melanoma, or Merkel cell carcinomas of the skin, to understand what the body does to the PH-762, and to observe how the tumor responds to the drug. Participants will receive four injections of PH-762 at weekly intervals, into a single tumor, followed by surgical removal of the tumor approximately two weeks later.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: George Washington University, Washington, District of Columbia
Conditions: Squamous Cell Carcinoma of the Skin, Malignant Melanoma of Skin, Merkel Cell Carcinoma of Skin
Register for Updates
Emicizumab in Patients With Acquired Hemophilia A
NCT05345197
Recruiting
This is a phase II multicenter open-label, single-arm prospective study to evaluate the efficacy of prophylactic emicizumab administered on a scheduled basis to prevent bleeds in patients with acquired hemophilia A (AHA).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Georgetown University, Washington, District of Columbia
Conditions: Acquired Hemophilia A
Register for Updates
ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement
NCT03735667
Recruiting
To evaluate safety and effectiveness of the ACURATE Transfemoral Aortic Valve System for transcatheter aortic valve replacement (TAVR) in subjects with severe native aortic stenosis who are indicated for TAVR.
Gender:
All
Ages:
All
Trial Updated:
06/10/2024
Locations: MedStar Washington Hospital Center, Washington, District of Columbia
Conditions: Aortic Stenosis
Register for Updates
Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia
NCT05254990
Recruiting
Primary objective: - To evaluate the efficacy of oral reparixin versus standard care alone in limiting disease progression in adult patients hospitalised for infectious pneumonia acquired in the community (CAP), including COVID-19. Secondary objectives: - To determine the effect of reparixin on several disease severity/progression measures including recovery, ventilatory free days and mortality. Safety objectives: - To evaluate the safety of oral reparixin versus placebo in the specific cli... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: MedStar Health Research Institute-Hyatteville, Maryland, Washington, District of Columbia
Conditions: Infectious Pneumonia, Severe COVID-19
Register for Updates